Our Focus on Research
The AAT Research group, a wholly owned subsidiary of Neurotech International Ltd, takes an innovative academic-industrial to scientific research. Formed by a team of talented individuals ranging from scientists, engineers and researchers, to marketers and software developers, we have solid experience in internationally funded projects and collaborations. The organization is above all dedicated to its own research: We want to improve people’s lives by developing and commercialising innovative, high quality medical solutions for the diagnosis and treatment of brain-related disorders. Our mission is to be a global leader in the field of neurophysiology by offering solutions suitable for home-use and clinics at affordable prices.
Our research focus currently includes:
Mente Autism is an easy-to-use, clinical-quality EEG device and effective neurofeedback system for safe home use by children with Autism Spectrum Disorder (ASD). It consists of a headband, an application (app) and a cloud component. Its unique technology creates “tailor-made” sonified neurofeedback for the children who use it. After each 40-minute morning therapy session, the system uploads the data registered during the session to the Cloud service via the Mente Autism App (using a Wi-Fi connection). Using this data, the Mente Autism cloud service generates a report that records and measures the child’s progress. Each session report can be viewed online or within the app. It is ideal to start using Mente Autism between 3 and 12 years of age. Positive effects are typically seen after four to eight weeks of daily 40-minute morning sessions.
AAT’s goal is for its medical technologies to always include a strong, reliable online platform system, with which its medical devices can interact and share data. The online platform also permits users, medical professionals, therapy administrators, and product specialists to remotely monitor and analyze progress. This platform is set to be a breakthrough in home-based therapies as medical professionals can monitor patients’ progress online through reports automatically generated per therapy session. These reports use data collected from the patient that is automatically analyzed online using novel computational methodology.
Epilepsy seizure prediction
AAT’s epilepsy seizure prediction project, currently under development, consists of a portable device which continuously monitors user’s EEG signals and communicates directly with a smartphone application. The goal is for this solution to automatically issue an alert to the patient and a carer 40 minutes prior to a frontal lobe epileptic seizure.
Depression and Anxiety
Anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States aged 18 and older (18 of the U.K. population suffers from some form of depression and 4.6 in children and young adults. AAT is studying the use and adaptation of Transcranial DC stimulation (tDCS) and transcranial magnetic stimulation (TMS) as a form of therapy for those suffering from depression, anxiety and insomnia.